Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$128.21 +0.2%	$99.05	$73.04 ▼ $128.34	$8.28B	0.84	1.18 million shs	4.65 million shs
ROIV Roivant Sciences	$11.47 +1.7%	$10.76	$8.73 ▼ $13.06	$7.80B	1.16	5.57 million shs	3.99 million shs
RVMD Revolution Medicines	$41.11 +0.8%	$38.46	$29.17 ▼ $62.40	$7.66B	1.1	1.53 million shs	1.25 million shs
XENE Xenon Pharmaceuticals	$32.80 +1.7%	$32.81	$26.74 ▼ $46.00	$2.52B	1.09	558,246 shs	1.06 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	-0.02%	-0.12%	+27.55%	+42.42%	+21.40%
ROIV Roivant Sciences	-0.79%	+0.62%	+2.64%	+8.25%	+6.72%
RVMD Revolution Medicines	-2.83%	+1.02%	-2.60%	+4.51%	+4.54%
XENE Xenon Pharmaceuticals	+0.31%	+5.91%	-10.01%	-8.30%	-15.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPMC Blueprint Medicines	1.1972 of 5 stars	2.2	2.0	0.0	2.5	0.8	0.6
ROIV Roivant Sciences	2.4436 of 5 stars	3.5	3.0	0.0	2.1	2.5	0.0
RVMD Revolution Medicines	4.4487 of 5 stars	4.5	1.0	4.7	3.3	2.5	0.0
XENE Xenon Pharmaceuticals	3.6802 of 5 stars	4.5	4.0	0.0	2.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMC Blueprint Medicines	2.32	Hold	$129.35	0.89% Upside
ROIV Roivant Sciences	3.00	Buy	$17.50	52.57% Upside
RVMD Revolution Medicines	3.00	Buy	$67.08	63.18% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$54.82	67.13% Upside

Current Analyst Ratings Breakdown

Latest XENE, BPMC, ROIV, and RVMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
6/3/2025	BPMC Blueprint Medicines	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$150.00 ➝ $135.00
5/28/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMC Blueprint Medicines	$562.12M	14.73	N/A	N/A	$4.67 per share	27.45
ROIV Roivant Sciences	$29.05M	268.38	N/A	N/A	$7.76 per share	1.48
RVMD Revolution Medicines	$742K	10,320.05	N/A	N/A	$11.09 per share	3.71
XENE Xenon Pharmaceuticals	$7.50M	335.58	N/A	N/A	$14.18 per share	2.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.25	N/A	-13.19%	-77.49%	-20.84%	7/30/2025 (Estimated)
ROIV Roivant Sciences	$4.35B	-$0.25	N/A	N/A	N/A	-119.54%	-14.05%	-12.81%	8/6/2025 (Estimated)
RVMD Revolution Medicines	-$436.37M	-$4.00	N/A	N/A	N/A	N/A	-33.67%	-30.08%	8/6/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$182.39M	-$3.23	N/A	N/A	N/A	N/A	-24.69%	-23.68%	8/6/2025 (Estimated)

Latest XENE, BPMC, ROIV, and RVMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/12/2025	Q1 2025	XENE Xenon Pharmaceuticals	-$0.90	-$0.83	+$0.07	-$0.83	$1.64 million	$7.50 million
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMC Blueprint Medicines	1.15	2.85	2.80
ROIV Roivant Sciences	N/A	37.91	37.91
RVMD Revolution Medicines	N/A	14.24	14.24
XENE Xenon Pharmaceuticals	N/A	22.21	22.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMC Blueprint Medicines	N/A
ROIV Roivant Sciences	64.76%
RVMD Revolution Medicines	94.34%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
BPMC Blueprint Medicines	4.21%
ROIV Roivant Sciences	7.90%
RVMD Revolution Medicines	8.20%
XENE Xenon Pharmaceuticals	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.22 million	Optionable
ROIV Roivant Sciences	860	679.81 million	657.18 million	Optionable
RVMD Revolution Medicines	250	186.27 million	154.76 million	Optionable
XENE Xenon Pharmaceuticals	210	76.73 million	72.03 million	Optionable

XENE, BPMC, ROIV, and RVMD Headlines

Recent News About These Companies

Brokers Set Expectations for XENE FY2026 Earnings

June 12 at 3:24 AM | americanbankingnews.com

Traders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

June 12 at 2:09 AM | marketbeat.com

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

June 11 at 12:36 PM | zacks.com

Cantor Fitzgerald Estimates XENE FY2026 Earnings

June 10 at 8:29 AM | marketbeat.com

Inhibitor Therapeutics (OTCMKTS:INTI) and Xenon Pharmaceuticals (NASDAQ:XENE) Financial Comparison

June 4, 2025 | americanbankingnews.com

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025 | globenewswire.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

June 2, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Bank of America Corp DE

May 31, 2025 | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 30, 2025 | globenewswire.com

Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)

May 30, 2025 | marketbeat.com

Ameriprise Financial Inc. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 28, 2025 | marketbeat.com

Woodline Partners LP Makes New $1.57 Million Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 27, 2025 | marketbeat.com

Two Sigma Investments LP Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 27, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Position Lifted by Millennium Management LLC

May 26, 2025 | marketbeat.com

Northern Trust Corp Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 26, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Two Sigma Advisers LP

May 25, 2025 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com

May 23, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by Brokerages

May 23, 2025 | marketbeat.com

Fair Value analysis proves accurate as XENE drops 37% from February 2024 peak

May 21, 2025 | investing.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Vestal Point Capital LP

May 21, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Sells 117,919 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE, BPMC, ROIV, and RVMD Company Descriptions

Blueprint Medicines NASDAQ:BPMC

$128.21 +0.26 (+0.20%)

As of 04:00 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$11.47 +0.19 (+1.68%)

As of 04:00 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Revolution Medicines NASDAQ:RVMD

$41.11 +0.32 (+0.78%)

As of 04:00 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Xenon Pharmaceuticals NASDAQ:XENE

$32.80 +0.54 (+1.67%)

As of 04:00 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time